Athira Pharma (LONA) Stock Price, News & Analysis

Company Overview

Athira Pharma, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for neurodegenerative diseases and other conditions involving impaired neuronal function. The company’s research has centered on the hepatocyte growth factor (HGF) biological pathway, which is associated with neuronal health, repair and regeneration.

Athira’s lead investigational product was fosgonimeton, also known as ATH-1017, an injectable therapy designed to activate the HGF/MET pathway. The candidate was studied for potential use in Alzheimer’s disease and other neurodegenerative disorders. Athira has not been a commercial-stage pharmaceutical company, and its products have been investigational rather than approved therapies.

Founded in 2011 and headquartered in the Seattle, Washington, area, Athira conducted its development activities primarily through clinical research programs in the United States. Leen Kawas, Ph.D., was a founder and served as the company’s chief executive officer during its earlier development and public-company period. Public references have generally associated Athira Pharma with the Nasdaq ticker ATHA rather than LONA; the ticker provided may therefore be inaccurate or refer to a different entity.

Key Stats

• Today's Range: $5.56 to $6.10
• 50-Day Range: $2.87 to $8.17
• 52-Week Range: $2.21 to $14.21
• Volume: 66,684 shs
• Average Volume: 482,347 shs
• Market Capitalization: $53.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.33
• Consensus Rating: Moderate Buy

Athira Pharma Stock Analysis - MarketRank™

Athira Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 192nd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Athira Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Athira Pharma has a consensus price target of $17.33, representing about 201.4% upside from its current price of $5.75.

Amount of Analyst Coverage

Athira Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Athira Pharma are expected to grow in the coming year, from ($2.67) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Athira Pharma is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athira Pharma is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Athira Pharma has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.27% of the float of Athira Pharma has been sold short.

Short Interest Ratio / Days to Cover

Athira Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Athira Pharma has recently decreased by 18.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athira Pharma does not currently pay a dividend.

Dividend Growth

Athira Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Athira Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.73% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LONA
• Previous Symbol: NASDAQ:ATHA
• CIK: 1620463
• Web: www.leonabio.com
• Phone: 425-620-8501
• Fax: N/A
• Employees: 19
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Athira Pharma: $17.33
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +201.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -411.58%
• Return on Assets: -225.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.01
• Quick Ratio: 7.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.98 per share
• Price / Book: 1.93

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 6,977,000
• Market Cap: $53.99 million
• Optionable: No Data
• Beta: 2.11